loading page

Differential Clinical Diagnosis and Prevalence Rate of Allergic Rhinitis, Asthma, and Chronic Obstructive Pulmonary Disease among COVID-19 Patients
  • Marian Boshra,
  • Mohammad F Mohammad,
  • Rania Sarhan
Marian Boshra
Beni Suef University Faculty of Pharmacy

Corresponding Author:mariansobhy31@yahoo.com

Author Profile
Mohammad F Mohammad
Beni Suef University Faculty of Medicine
Author Profile
Rania Sarhan
Beni Suef University Faculty of Pharmacy
Author Profile

Abstract

Background: There is a great need to make a rapid differential clinical diagnosis of COVID-19 among respiratory disease patients and determining the prevalence rate of these diseases among the COVID-19 population. Method: Approximately 522 patients with allergic rhinitis, asthma, COPD, and COVID-19 were analyzed for demographic and clinical features. Radiological features were analyzed only for COVID-19 patients. Results: COPD and asthma were more common among COVID-19 patients than allergic rhinitis. All chest CT scans of COVID-19 patients showed bilateral ground-glass opacity. Fever, dry cough, diarrhea, loss of sense of smell and taste, shortness of breath, and blue lips were significantly higher in all COVID-19 patients compared to COPD, asthma, and allergic rhinitis patients. Conclusion: The presence of clinical symptoms such as fever, dry cough, diarrhea, loss of sense of smell and taste, shortness of breath, and blue lips in COVID-19 patients, can be used for differential diagnosis between COVID-19 patients and other respiratory diseases. Then, the diagnosis can be confirmed by chest CT scan for COVID-19 patients without the need for a nasopharyngeal swab or PCR test, especially in epidemic countries. Allergic rhinitis patients are the least exposed to COVID-19 infection among other respiratory disease patients.
04 Feb 2021Submitted to International Journal of Clinical Practice
05 Feb 2021Submission Checks Completed
05 Feb 2021Assigned to Editor
16 Feb 2021Reviewer(s) Assigned
01 May 2021Review(s) Completed, Editorial Evaluation Pending
14 May 20211st Revision Received
16 May 2021Submission Checks Completed
16 May 2021Assigned to Editor
16 May 2021Review(s) Completed, Editorial Evaluation Pending
10 Jun 2021Editorial Decision: Accept